News

Elucid Bioimaging Inc, announced today that it has received FDA 510(k) clearance to market its vascuCAP software (K163071) for evaluating CT images of patients with atherosclerosis.

May 25, 2017
May 25th, 2017 Wenham Massachusetts – Elucid Bioimaging Inc, announced today that it has received FDA 510(k) clearance to market its vascuCAP software (K163071) for evaluating CT images of patients with atherosclerosis. “This is a major milestone in the Elucid’s commercialization program”, remarked John Garber, Chief Executive Officer, “our visualization and measurement tools will be… View Article

Elucid Bioimaging is pleased to announce that they have met their recruiting targets for the Q-CAMP study

February 22, 2017
Wenham, MA–(BUSINESS WIRE) Elucid Bioimaging is pleased to announce that they have met their recruiting targets for the Q-CAMP study, enrollment has been completed and preliminary results will be announced in early June. Elucid started the Non-invasive Computer-Aided Phenotyping of Vasculopathy (Q-CAMP) study in 2014. Q-CAMP is a cross-sectional study of patients undergoing endarterectomy of… View Article

John Garber promoted to CEO of Elucid Bioimaging

February 13, 2017
February 10, 2017 Wenham, MA–(BUSINESS WIRE) The Board of Directors of Elucid Bioimaging announce that they have promoted John Garber to Chief Executive Officer, effective February 14, 2017. John’s mission will be the commercial launch of Elucid’s imaging biomarkers business and its expansion into the immune oncology space. As of this date, Elucid’s founder, Andrew… View Article

Elucid BioImaging Expands Executive Team with Appointment of John Garber

January 16, 2017
Wenham, MA (January 12th, 2017) — Elucid Bioimaging, Inc. (“Elucid”), a leader in quantitative medical imaging, is proud to announce the expansion of its executive team with the appointment of John T Garber, MBA, as Vice President of Sales and Business Development. John will strengthen Elucid’s operations and executive management and lead commercialization of their… View Article

National Institutes of Health awards Elucid Bioimaging 2nd year of SBIR grant “vascuCAP: Non-invasive Computer-Aided Phenotyping of Vasculopathy.

June 6, 2016
National Institutes of Health awards Elucid Bioimaging SBIR grant to establish vascuCAP as fit for use in both personalized medicine as well as drug development. August 2015 Elucid Bioimaging is pleased to be in receipt of a Small Business Innovation Research (SBIR) grant award notice from the National Heart, Lung, and Blood Institute of the… View Article

Dr. Michael Rosol joins staff as Senior Director of Business Development

May 1, 2016
Michael Rosol, Ph.D., Senior Director of Business Development   Dr. Rosol is a biomedical imaging professional with extensive commercial experience, notably in his prior position as Head of the Translational Imaging Group at Novartis Pharmaceuticals, which provides him with deep insights into the needs of industry for the development, validation, and implementation of imaging biomarkers… View Article

Issued patent: Classification of Biological Tissue by Multi-Mode Data Registration, Segmentation, and Characterization. US Patent 9,235,887

January 12, 2016